Table 3 Effect of repeated oral dosing of PF-06427878 on serum fasting (studies B7871002 and B7871005) and postprandial (study B7871005) TG concentrations in humans.

Effect of repeated oral dosing of PF-06427878 on serum fasting (studies B7871002 and B7871005) and postprandial (study B7871005) TG concentrations in humans.. Data are presented from studies B7871002 and B7871005 separately to showcase the effect with increasing doses of PF-06427878 with comparison to within-study placebo. Daily administration of PF-06427878 was divided Q8H with a meal. CI, confidence interval; LS, least squares; and TG, triglycerides.

Dose (mg/day)n% Change from baselinePlacebo-adjusted % change from baseline
Adjusted
geometric LS
means
80% CIAdjusted
geometric LS
means
80% CIP
Fasting serum TG concentrations
Study B7871002
Placebo8−0.9−10.1 to 9.2
PF-06427878, 15 mg6−8.2−17.9 to 2.7−7.3−20.1 to 7.50.5086
PF-06427878, 45 mg8−5.4−14.2 to 4.2−4.5−16.8 to 9.50.6608
PF-06427878, 150 mg8−22.5−29.7 to −14.6−21.8−31.8 to −10.30.0254
PF-06427878, 450 mg8−9.5−17.9 to −0.3−8.7−20.38 to 4.70.3928
Study B7871005
Placebo12−24.5−34.4 to −13.1
PF-06427878, 1500 mg12−16.4−27.3 to −3.810.8−9.2 to 35.00.5034
Postprandial TG concentrations
Study B7871005
Placebo12−21.0−29.9 to −10.9
PF-06427878, 1500 mg12−20.0−29.4 to −9.21.3−14.9 to 20.50.9236